KVANTO-PAYMENT-SOLUTIONS
6.2.2020 09:02:10 CET | Business Wire | Press release
For Pure Health inc. (FPH) has signed a partnership agreement with Kvanto Payment Services A/S (hereafter Kvanto). FPH provides sales all over the globe. All numbers and assumptions are based on previous first-hand experience with similar setups and products. And has made it before and they have entered with Kvanto and using the Payment Gateway, this has a large opportunity.
“FPH was looking for a partner to handle payments solution. One of the most important things for FPH is that customers experience has a smooth and secure checkout when buying our products from our website.
Kvanto Payment services not only provided us with this solution but also helped us set up the system, quickly and seamlessly. Furthermore, FPH has trusted Kvanto Payment Services with helping FPH with administration, technical, and development.
This special cooperation we have not been able to find elsewhere. From the start of this cooperation, we have made this as a focus development case, and we are now moving it to a slot of large opportunities of 250M € turnover a year and our aim is larger, and Kvanto stands the challenge and we have been satisfying so fare.
Allan Djurhuus
CEO, FPH Inc
.”
Benefits compared to other solution partners
Kvanto has an MPI security Solution, it works outside Europe, and that’s where we have most of the clients in FPH. Kvanto makes sure the merchant’s customer and the cardholder are the same person by sending a code to the customer's cell phone, which the customer must fill into the payment window before the payment is approved.
FPH has made this happen, through our marketing corporation with Konnektive CRM in US/PR and we have worked with Konnektive CRM for years now, and it has been a huge success, and we are so delighted to manage to get both Kvanto and Konnektive CRM together, and we have now one solution, and that saves us a large amount of time and money, we can´s understand why people not are managing this as it has to be, and as Konnektive is saying.
“Time is money.
With hundreds of integrations through Konnektive, you’ll never be scrambling to find your data by going to multiple systems. We put everything you need at your fingertips; all in one place!
Konnektive CRM was designed to Automate
and Synchronize
Your Entire Business with the easiest, most intuitive user interface.
Brian Bolerjack,
Konnektive CRM”
Kvanto cooperation with both the system provider and customer
Kvanto has made an option and an opportunity by creating this cooperation, to manage a whole platform, by offering the Kvanto ESB Payment Gateway, and support the individual customer and the whole group of Konnektive CRM platform solution, as a trusted partner. Kvanto has proved to be highlighted as a service provider that can handle payment transactions across the payment ECO-system, and even if you are making the payment happen in Europe or elsewhere, we can carry the solution to a new level of security by Kvanto MPI solution.
Value proposition
By managing this, and through the Kvanto Gateway Solution, it will be possible to draw more potential clients into our merchants, and our expectation of this cooperation is more than 12 Mill $ in turnover a year, on this case alone.
And the options for new clients is much higher, and we can multiply this 3-4 times.
This is an optimizing way of creating new clients, and we have today two new clients, that bring more merchants in through this cooperation, and we expect to reach some 15-22 clients with the support we have from Konnektive CRM staff and PR from FPH.
About Kvanto Payment Solutions
Kvanto is a Payment Solution Provider company that provides simple, flexible, and cost-efficient payment solutions on the global market. Through experience and knowledge does Kvanto challenge current structures and procedures in the established market.
Kvanto strives to be a one-stop-shop for payments with cross border solutions for merchants and the leading EMEA/APAC multi-connectivity payment solutions provider measured in processing volume while being profitable.
For further investor enquires
Listing Partners LLC
support@listingpartners.lu
All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Kvanto Payment Systems A/S is under no obligation to (and expressly disclaim any such obligation to) update or alters our forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
